Validea Detailed Fundamental Analysis

Validea's guru fundamental report rates Thermo Fisher Scientific (TMO) at 77% using Partha Mohanram's P/B Growth Investor model, a strategy recognized for identifying outperforming growth stocks among low book-to-market companies. As a large-cap medical equipment stock, TMO largely aligns with the model's criteria for sustained growth, passing key metrics like return on assets and cash flow. However, its score falls just below the 80% threshold for 'some interest' due to specific fails in advertising and R&D to assets, suggesting a nuanced outlook for growth-focused investors employing this academically-backed methodology.

Analysis

Thermo Fisher Scientific Inc. (TMO) receives a moderately positive rating of 77% from Validea's P/B Growth Investor model, which is based on the academic strategy of Partha Mohanram for identifying sustainable growth stocks among low book-to-market companies. This score places TMO just below the 80% threshold that typically signals active interest from the strategy. The company demonstrates significant fundamental strength by passing key tests for its low book-to-market ratio, return on assets (ROA), and cash flow from operations relative to assets. Furthermore, TMO exhibits stability, passing criteria for variance in both ROA and sales. However, the model flags two critical weaknesses related to future growth drivers: TMO fails the tests for both Advertising to Assets and Research and Development to Assets. This suggests that while the company's current operational efficiency and profitability are strong, its investment in marketing and innovation, relative to its size, may not meet the model's criteria for ensuring sustained long-term growth.

Key Decisions for Investors

• Investors should weigh TMO's strong current fundamentals, such as high return on assets and robust cash flow, against the potential risk flagged by its underperformance on R&D and advertising investment metrics.
• Given the 77% score is just below the model's 80% interest threshold, a prospective investor might consider this a 'watch list' candidate, pending further due diligence on the company's long-term growth strategy and capital allocation.
• For investors utilizing a 'Growth at a Reasonable Price' (GARP) framework, TMO's positive score on value (low book-to-market) and profitability metrics is appealing, but the concerns about growth reinvestment warrant careful monitoring of future capital and R&D expenditures.